News
EDT Novavax (NVAX) down 10% after WSJ report on FDA request for additional vaccine trialStay Ahead of the Market: Discover outperforming ...
Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's ...
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...
Investing.com -- Novavax (NASDAQ: NVAX) shares surged 13% following the biotechnology company’s optimism about its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results